NK012 is a 'nanodevice' formulation of SN-38 (an irinotecan metabolite). NK012 is an SN-38-releasing polymeric micelle constructed by covalently attaching...
2 KB (203 words) - 21:29, 8 February 2023
interactive pathway map can be edited at WikiPathways: "IrinotecanPathway_WP229". NK012, a nanodevice formulation of SN-38 Sacituzumab govitecan, an antibody-drug...
3 KB (225 words) - 16:48, 11 January 2024
being tested in clinical trials, including the PARP inhibitor BSI 201, NK012. A novel antibody-drug conjugate known as glembatumumab vedotin (CDX-011)...
28 KB (3,411 words) - 03:40, 14 June 2024